Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2882767rdf:typepubmed:Citationlld:pubmed
pubmed-article:2882767lifeskim:mentionsumls-concept:C0039468lld:lifeskim
pubmed-article:2882767lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:2882767lifeskim:mentionsumls-concept:C0871935lld:lifeskim
pubmed-article:2882767pubmed:issue4lld:pubmed
pubmed-article:2882767pubmed:dateCreated1987-6-12lld:pubmed
pubmed-article:2882767pubmed:abstractTextTwo injectable forms of temazepam, in 90% propylene glycol or 40% salicylic acid, were studied in volunteers, and before surgery in healthy patients. The volunteers also received two forms (capsule and elixir) by mouth. The salicylate preparation was painful on injection and both i.v. formulations caused an unacceptably high incidence of venous thrombosis. Temazepam was detected in plasma earlier following the elixir preparation than the capsule. Plasma concentrations were similar following both injectable preparations. The potency of i.v. temazepam in inducing drowsiness in patients was much less than expected and doses greater than 0.6 mg kg-1 were required to produce adequate sedation. There was a significant reduction in thiopentone induction dose in patients receiving temazepam i.v.lld:pubmed
pubmed-article:2882767pubmed:languageenglld:pubmed
pubmed-article:2882767pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2882767pubmed:citationSubsetIMlld:pubmed
pubmed-article:2882767pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2882767pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2882767pubmed:statusMEDLINElld:pubmed
pubmed-article:2882767pubmed:monthAprlld:pubmed
pubmed-article:2882767pubmed:issn0007-0912lld:pubmed
pubmed-article:2882767pubmed:authorpubmed-author:DundeeJ WJWlld:pubmed
pubmed-article:2882767pubmed:authorpubmed-author:CarlisleR JRJlld:pubmed
pubmed-article:2882767pubmed:authorpubmed-author:HallidayN JNJlld:pubmed
pubmed-article:2882767pubmed:authorpubmed-author:McCleanEElld:pubmed
pubmed-article:2882767pubmed:issnTypePrintlld:pubmed
pubmed-article:2882767pubmed:volume59lld:pubmed
pubmed-article:2882767pubmed:ownerNLMlld:pubmed
pubmed-article:2882767pubmed:authorsCompleteYlld:pubmed
pubmed-article:2882767pubmed:pagination465-7lld:pubmed
pubmed-article:2882767pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2882767pubmed:meshHeadingpubmed-meshheading:2882767-...lld:pubmed
pubmed-article:2882767pubmed:meshHeadingpubmed-meshheading:2882767-...lld:pubmed
pubmed-article:2882767pubmed:meshHeadingpubmed-meshheading:2882767-...lld:pubmed
pubmed-article:2882767pubmed:meshHeadingpubmed-meshheading:2882767-...lld:pubmed
pubmed-article:2882767pubmed:meshHeadingpubmed-meshheading:2882767-...lld:pubmed
pubmed-article:2882767pubmed:meshHeadingpubmed-meshheading:2882767-...lld:pubmed
pubmed-article:2882767pubmed:meshHeadingpubmed-meshheading:2882767-...lld:pubmed
pubmed-article:2882767pubmed:meshHeadingpubmed-meshheading:2882767-...lld:pubmed
pubmed-article:2882767pubmed:meshHeadingpubmed-meshheading:2882767-...lld:pubmed
pubmed-article:2882767pubmed:meshHeadingpubmed-meshheading:2882767-...lld:pubmed
pubmed-article:2882767pubmed:meshHeadingpubmed-meshheading:2882767-...lld:pubmed
pubmed-article:2882767pubmed:meshHeadingpubmed-meshheading:2882767-...lld:pubmed
pubmed-article:2882767pubmed:year1987lld:pubmed
pubmed-article:2882767pubmed:articleTitleI.v. temazepam: theoretical and clinical considerations.lld:pubmed
pubmed-article:2882767pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2882767pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:2882767pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:2882767pubmed:publicationTypeRandomized Controlled Triallld:pubmed